{"title":"Hot spots and trends related to chemotherapy in nasopharyngeal carcinoma [2014-2024]: a bibliometric study.","authors":"Han Deng, Peng Zhou, Suyu Wang, Qicheng Zhang","doi":"10.21037/cco-25-12","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy has played an essential role in nasopharyngeal carcinoma (NPC) management since the 1980s, when its radiosensitizing effects were first recognized. The landmark Intergroup 0099 trial established concurrent cisplatin-based chemoradiotherapy as the standard for locoregionally advanced NPC, demonstrating significant survival benefits over radiotherapy alone. As an Epstein-Barr virus (EBV)-associated malignancy with distinct geographical distribution (endemic in southern China and Southeast Asia), NPC presents unique therapeutic challenges. Subsequent studies refined chemotherapy sequencing, introducing induction approaches to address distant failure risks and adjuvant strategies for high-risk cases. The evolution of chemotherapy regimens has been particularly crucial given NPC's anatomical complexity and surgical limitations. Recent years have seen growing emphasis on balancing efficacy with toxicity reduction, especially for endemic populations where treatment-related morbidity significantly impacts quality of life. The published documents of the last 10 years were analyzed by bibliometrics and visualization in order to assess the focus and trend of chemotherapy research in NPC.</p><p><strong>Methods: </strong>Based on Web of Science Core Collection (WoSCC) database, the relevant literatures during the period 2014-2024 were searched and visualized the countries, authors, institutions, and keywords through CiteSpace and VOSviewer to understand the hotspots and trends of chemotherapy in NPC treatment.</p><p><strong>Results: </strong>In the past decade, chemotherapy has gained more and more attention in NPC, and the leading countries are China and the United States, and the author with the most publications is Jun Ma. Sun Yat-sen University is the institution with the most publications.</p><p><strong>Conclusions: </strong>Our study has learned that combination chemotherapy and survival prognosis are the focus of attention in this field, and bibliometrics can help us to have a better understanding and management of it.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-25-12","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chemotherapy has played an essential role in nasopharyngeal carcinoma (NPC) management since the 1980s, when its radiosensitizing effects were first recognized. The landmark Intergroup 0099 trial established concurrent cisplatin-based chemoradiotherapy as the standard for locoregionally advanced NPC, demonstrating significant survival benefits over radiotherapy alone. As an Epstein-Barr virus (EBV)-associated malignancy with distinct geographical distribution (endemic in southern China and Southeast Asia), NPC presents unique therapeutic challenges. Subsequent studies refined chemotherapy sequencing, introducing induction approaches to address distant failure risks and adjuvant strategies for high-risk cases. The evolution of chemotherapy regimens has been particularly crucial given NPC's anatomical complexity and surgical limitations. Recent years have seen growing emphasis on balancing efficacy with toxicity reduction, especially for endemic populations where treatment-related morbidity significantly impacts quality of life. The published documents of the last 10 years were analyzed by bibliometrics and visualization in order to assess the focus and trend of chemotherapy research in NPC.
Methods: Based on Web of Science Core Collection (WoSCC) database, the relevant literatures during the period 2014-2024 were searched and visualized the countries, authors, institutions, and keywords through CiteSpace and VOSviewer to understand the hotspots and trends of chemotherapy in NPC treatment.
Results: In the past decade, chemotherapy has gained more and more attention in NPC, and the leading countries are China and the United States, and the author with the most publications is Jun Ma. Sun Yat-sen University is the institution with the most publications.
Conclusions: Our study has learned that combination chemotherapy and survival prognosis are the focus of attention in this field, and bibliometrics can help us to have a better understanding and management of it.
期刊介绍：
The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
